Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Radiation Injuries 1Neoplasms 1Head and Neck Neoplasms 1Developmental Disabilities 1Congenital Abnormalities 1Colonic Neoplasms 1

Interventions

Oxaliplatin 27Fluorouracil 23Leucovorin 22Cetuximab 22Bevacizumab 21Nivolumab 16Capecitabine 16Irinotecan 15pembrolizumab 11Magnetic Resonance Spectroscopy 11Specimen Handling 10encorafenib 8Folfox protocol 7trifluridine tipiracil drug combination 6Ipilimumab 6Exercise 6fludarabine 5cemiplimab 5Trastuzumab 5Gemcitabine 5Cyclophosphamide 5Cisplatin 5Blood Specimen Collection 5Biopsy 5regorafenib 4pertuzumab 4adagrasib 4Trifluridine 4Pemetrexed 4Immune Checkpoint Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Radiography, Panoramic × 1 year × Clear all
NCT00002968 2026-06-01

Edrecolomab in Treating Patients With Stage II Colon Cancer

National Cancer Institute (NCI)

Phase 3 Completed
2,100 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡